LMR Partners’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.18M Buy
+47,000
New +$4.52M 0.01% 738
2024
Q2
– Sell
-11,093
Closed -$421K – 1311
2024
Q1
$421K Buy
+11,093
New +$321K ﹤0.01% 784
2022
Q4
– Sell
-769
Closed -$10K – 1265
2022
Q3
$10K Hold
769
– – ﹤0.01% 1190
2022
Q2
$10K Buy
+769
New +$26.9K ﹤0.01% 1256

Other funds holding SYRE

LMR Partners's SYRE Position: Q3 2026 in Review

LMR Partners opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 47,000 shares worth $4.18M. The stake represents 0.01% of the portfolio and ranks #738 among its holdings. This is a return to the name: LMR Partners previously reported a position in SYRE as recently as Q1 2024.

LMR Partners first reported a position in SYRE in Q2 2022 and has held it in 4 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • LMR Partners held 47,000 shares of Spyre Therapeutics worth $4.18M as of Q3 2026.
  • Spyre Therapeutics was a new LMR Partners position in Q3 2026.
  • Spyre Therapeutics made up 0.01% of LMR Partners's portfolio in Q3 2026, its #738 holding.
  • LMR Partners first reported a position in Spyre Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.